Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Donanemab, another controversial drug which costs about 60-80,000 per year, shows a 0.7 point difference at 76 weeks, which is roughly 33% slower than placebo
Fibroblasts also secrete substances, like vascular endothelial growth factor (VEGF), which promote the growth of blood vessels
Some of my key takeaways: GLP-1 therapy is not just about glycemic control, it has a broader role in weight management and cardiometabolic risk reduction
But if Im being real, the price tag gave me pause
Diabetologia 36 (8), 741744
US$ 26.72
US$ 28.85
US$ 25.82
